Madeleine J. Karpinski

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects.

The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects.

Journal: Seminars in nuclear medicine

Published: December 10, 2025

PSMA-PET response under [177Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteria.

PSMA-PET response under [177Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteria.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 08, 2025

Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry.

Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 04, 2025

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.

Journal: The Lancet. Oncology

Published: September 24, 2025

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry.

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry.

Journal: European urology

Published: July 01, 2025

Reply to Zhengbo Pan, Run Shi, and Zhaokai Zhou's Letter to the Editor - Re: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bögemann, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. 2025;88:484-495.

Reply to Zhengbo Pan, Run Shi, and Zhaokai Zhou's Letter to the Editor - Re: Madeleine J. Karpinski, Kambiz Rahbar, Martin Bögemann, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. 2025;88:484-495.

Journal: European urology

Published: June 06, 2025

Prostate-specific membrane antigen positron-emission tomography for novel risk-stratification of biochemical recurrence.

Prostate-specific membrane antigen positron-emission tomography for novel risk-stratification of biochemical recurrence.

Journal: Current opinion in urology

Published: April 24, 2025

Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC.

Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 03, 2025

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.

Journal: European urology

Published: January 23, 2025

The Probability of Remaining Under Active Surveillance for Localized Prostate Cancer: An Analysis of Young Patients in the Framework of the Multicenter ProjuMa Registry Study.

The Probability of Remaining Under Active Surveillance for Localized Prostate Cancer: An Analysis of Young Patients in the Framework of the Multicenter ProjuMa Registry Study.

Journal: Deutsches Arzteblatt international

Published: December 18, 2024

PSMA-PET research: addressing challenges and prospects - Authors' reply.

PSMA-PET research: addressing challenges and prospects - Authors' reply.

Journal: The Lancet. Oncology

Published: October 04, 2024

Mortality from prostate cancer in the years 2007-2021 in North Rhine-Westphalia, Germany.

Mortality from prostate cancer in the years 2007-2021 in North Rhine-Westphalia, Germany.

Journal: BMC urology

Published: June 09, 2024

Showing 1-12 of 14

Last Updated: 09/26/2026